CARLSBAD, CALIFORNIA, June 10, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a pioneer in innovative spinal solutions, proudly announces that its proprietary SiLO™ Sacroiliac (SI) Joint Fusion System has been successfully used in over 2,500 procedures across the United States. This major milestone underscores the company’s accelerating growth and increasing adoption of its minimally invasive technology by surgeons nationwide. Aurora’s SiLO™ p ...

Core Insights - Aurora Spine Corporation has received FDA 510(k) clearance for its AERO™ Facet Fusion System, marking a significant advancement in its product pipeline [1][5] Product Overview - The AERO MIS Facet Fusion System is a patent-pending device designed for minimally invasive treatment of facet joint-related pain or instability, applicable from spinal levels C2 to S1 [2] - The system can be utilized as a stand-alone procedure or in conjunction with larger spinal fusion surgeries [2] Clinical Application - AERO is intended for patients with mechanical back pain, minor instability, or degenerative joint disease who have not responded to conservative therapies, promoting bone fusion while minimizing soft tissue disruption [3] - Initial surgeries using the AERO system are anticipated to commence in late Q3 2025, with leading spine surgeons participating in a clinical study to validate clinical outcomes and long-term benefits [4] Company Statements - The President and CEO of Aurora Spine expressed enthusiasm about the FDA clearance, highlighting the system's design for physicians treating facet joint issues and its potential as a growth driver for the company [5] - The Chief Technology Officer emphasized the thoughtful engineering behind the AERO system, reflecting the company's commitment to improving patient care through innovation [5] Company Background - Aurora Spine focuses on developing new solutions in the spinal implant market through proprietary, minimally invasive, and regenerative technologies aimed at enhancing surgical outcomes [6]